Central Pacific Bank Trust Division Raises Holdings in Humana Inc. $HUM

Central Pacific Bank Trust Division increased its holdings in Humana Inc. (NYSE:HUM) by 12.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 3,245 shares of the insurance provider’s stock after acquiring an additional 350 shares during the period. Central Pacific Bank Trust Division’s holdings in Humana were worth $793,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in HUM. Janney Montgomery Scott LLC purchased a new position in shares of Humana during the first quarter worth $1,309,000. Envestnet Asset Management Inc. boosted its position in shares of Humana by 2.4% during the first quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock worth $33,256,000 after buying an additional 2,950 shares during the period. Circle Wealth Management LLC purchased a new position in shares of Humana during the first quarter worth $425,000. Rhumbline Advisers boosted its position in shares of Humana by 3.3% during the first quarter. Rhumbline Advisers now owns 246,037 shares of the insurance provider’s stock worth $65,101,000 after buying an additional 7,909 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Humana by 3.4% during the first quarter. Arizona State Retirement System now owns 35,337 shares of the insurance provider’s stock worth $9,350,000 after buying an additional 1,165 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Down 0.8%

NYSE:HUM opened at $276.36 on Friday. Humana Inc. has a 12-month low of $206.87 and a 12-month high of $325.75. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The firm has a market cap of $33.24 billion, a PE ratio of 21.21, a price-to-earnings-growth ratio of 1.64 and a beta of 0.44. The stock has a fifty day moving average price of $265.34 and a 200 day moving average price of $257.20.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter in the prior year, the business earned $6.96 earnings per share. The firm’s quarterly revenue was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. Humana’s dividend payout ratio (DPR) is currently 27.17%.

Analyst Upgrades and Downgrades

HUM has been the subject of several research analyst reports. Robert W. Baird lowered their price target on Humana from $300.00 to $297.00 and set a “neutral” rating for the company in a research report on Friday, July 25th. Morgan Stanley lowered their price target on Humana from $290.00 to $277.00 and set an “equal weight” rating for the company in a research report on Thursday, July 31st. Truist Financial lowered their price target on Humana from $280.00 to $260.00 and set a “hold” rating for the company in a research report on Wednesday, July 16th. Royal Bank Of Canada lifted their target price on Humana from $283.00 to $322.00 and gave the company an “outperform” rating in a report on Thursday, August 21st. Finally, Barclays lifted their target price on Humana from $275.00 to $315.00 and gave the company an “equal weight” rating in a report on Friday, September 5th. Seven research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. Based on data from MarketBeat, Humana presently has a consensus rating of “Hold” and a consensus target price of $289.24.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.